- Healthcare Professionals
- Latest research
- Clinical trials
- Checkmate-078
Bladder Cancer
Checkmate-078
A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC.
Trial overview
Topic
Bladder cancer
Description
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer.
Eligibility criteria
To be considered for the study you must meet the following criteria:
- Muscle invasive bladder cancer
- Planned for curative surgery
Study details
The treatment involves pre-surgery chemotherapy with or without Nivolumab and BMS-98620. Curative surgery, followed by further treatment with Nivolumab and BMS-986205. While on treatment there will be regular blood tests, urine tests, cystoscopies, and scans to monitor progress. At completion of treatment the study will continue to follow your progress.
Further information
For more information on this clinical trial here.
Location